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In an effort to understand major cost drivers and assess processing risk, Juno Therapeutics has developed a 
plant simulation of its global manufacturing network.  With this simulation, Juno can assess the impact various 
control levers and sources of variability will have on key performance metrics.  Juno has the ability to modify 
various aspects of its manufacturing operations, such as process design, staffing totals, shift schedules, facility 
configuration, and activity prioritization.  Various sources of variability, such as time of patient specific raw 
material arrival at the plant, treatment rescheduling, and unit operation duration, will need to be mitigated in 
order to ensure robust manufacturing.  In turn, with a representative simulation in place, optimization techniques 
can be leveraged in an effort to maximize the number of treated patients and revenue, while minimizing cost of 
goods and product cycle time.  This work helps inform feasibility of future manufacturing paradigms and process 
design.  An overview of Juno’s simulation and optimization methodology is presented here.  Evaluations and 
trade-offs of point-of-care vs. centralized manufacturing and workstation vs. flexible facility configurations are 
presented. 
 
